Navigation
banner
Together we Drive the Future

Biomarker Summit

2017-08-192018-01-152017-11-15
EARLY BIRD DISCOUNT! Register by Nov 15, 2017 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 speakers list is currently being formed.

Please come back and visit this page for updates.

BELOW ARE THE SPEAKERS FROM 2017.

PLENARY KEYNOTE SPEAKERS
Kenneth Emancipator

Kenneth Emancipator
Executive Medical Director and Head of Companion Diagnostics
Merck
Kenneth Emancipator
Executive Medical Director and Head of Companion Diagnostics
Merck
 
About Speaker:

Kenneth Emancipator, MD, DABP is a nationally renowned pathologist who is the Executive Medical Director and Head of Companion Diagnostics for Merck & Company. He led the Merck team which partnered with Dako North America to develop the PD-L1 test, which identifies those non-small cell lung cancer patients most likely to benefit from Keytruda® (pembrolizumab), and which is the first companion diagnostic in cancer immunotherapy to be approved by the US Food and Drug Administration. The PD-L1 test enabled Keytruda to become the first immunotherapy to be approved for first-line treatment of non-small cell lung cancer. Dr. Emancipator was one of six members of the Keytruda Team to receive the 2015 PhRMA Research and Hope Award for Biopharmaceutical Industry Research on behalf of Merck.

Dr. Emancipator’s primary interest has always been the role of diagnostic tests in driving clinical decisions. His current focus is personalized medicine, with a special emphasis on precision immuno-oncology. He has in-depth experience with in vitro diagnostics from every perspective, having served as medical director both for academic clinical laboratories and for diagnostics manufacturers, and having been a reviewer for the US Food and Drug Administration, before joining the pharmaceutical industry.

Dr. Emancipator received his A.B. degree from Harvard University and his MD from St. Louis University. He completed his medical internship at Westchester County Medical Center and his pathology residency at the State University of New York at Stony Brook. He has held appointments at the US National Institutes of Health, the US Food and Drug Administration, Cornell University, Beth Israel Medical Center, Bayer Healthcare, Siemens Healthcare, and Abbott Molecular prior to joining Merck. He also has held various leadership positions with the American Society for Clinical Pathology (ASCP), including chairing its Council on Clinical Chemistry, serving on its Board of Certification, serving on its Finance Committee, and eventually being elected Treasurer and to the Board of Directors. He continues to serve as a reviewer for ASCP’s American Journal of Clinical Pathology.

Dr. Emancipator has authored over 100 publications and has presented at more than 100 extramural programs. When not in his office at Merck, he is most likely to be found along the beaches and coastal waterways of Eastern Long Island.

PLENARY SPEAKERS
Bruce W.M. Jordan

Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
Bruce W.M. Jordan
Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions
Roche Diagnostics
 
About Speaker:

Dr. Bruce W.M. Jordan, Ph.D, FIBMS
VP, International Business Leader – Personalised Healthcare Solutions

Bruce joined the Roche Pharmaceuticals Herceptin team in Basel in 2005, leading the global HER2 Testing/Companion Diagnostics (CDx) activities. Since January 2013 he is VP - International Business Leader – Personalised Healthcare Solutions at Roche Diagnostics – Centralised and Pont of Care Solutions at their HQ in Rotkreuz, Switzerland.

He has worked on CDx development & commercialization out of both the Pharmaceuticals and Diagnostics Divisions over the past 11 years at Roche, across therapeutic areas such as Neurology, Immunology, Fertility and Oncology.

Bruce trained in Laboratory Medicine, graduating from the University of Portsmouth U.K. in 1994 with a BSc. (Hons.) Biomedical Sciences, subsequently gaining State Registration in Haematology and Transfusion Medicine at Southampton General Hospital. He has also worked at the Royal Marsden Hospital, London, and has a Ph.D. in cancer research from the University of Würzburg in Germany.

Bruce has also represented the diagnostics industry as a Corporate Representative at the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), and is a Fellow of the Institute of Biomedical Sciences (FIBMS) in the U.K., and a member of the European Society of Pharmacogenomics and Personalised Therapy (ESPT)

Stephen Albert Johnston

Stephen Albert Johnston
Director, Center for Innovations in Medicine; Professor, School of Life Sciences, Arizona State University
CEO, Calviri
Stephen Albert Johnston
Director, Center for Innovations in Medicine; Professor, School of Life Sciences, Arizona State University
CEO, Calviri
 
About Speaker:

Dr. Johnston directs the Center for Innovations in Medicine (CIM) at the Biodesign Institute. CIM is unique in its focus on inventing disruptive technologies in biomedicine. The mission is to contribute to the transformation of medicine through technologies that allow prevention, early detection and new therapeutic treatment of disease. Toward this goal CIM is focusing on developing three of his inventions. One project is to create a universal, preventative cancer vaccine. A second is to develop a system for continuous, comprehensive, cheap health monitoring. The third is based on an invention for making new therapeutics and targeted anti-infectives.
Johnston largely focuses on invention. He was inventor/ co-inventor of pathogen derived resistance, mitochondrial transformation, TEV protease system, the gene gun, gene immunization, expression library immunization, linear expression elements, synbodies and immunosignaturing. He was professor and director of the Center for Biomedical Inventions at UT-Southwestern Medical Center and Professor of Biology and Biomedical Engineering at Duke University before moving to ASU.

Nuno Bandeira

Nuno Bandeira
Associate Professor, Computer Science and Engineering; Executive Director, Center for Computational Mass Spectrometry
University of California, San Diego
Nuno Bandeira
Associate Professor, Computer Science and Engineering; Executive Director, Center for Computational Mass Spectrometry
University of California, San Diego
 
About Speaker:

Nuno Bandeira received his B.S. in Computer Science (1997); New University of Lisbon, Portugal; M.Sc. in Applied Artificial Intelligence (2001); New University of Lisbon, Portugal; Ph. D. in Computer Science and Bioinformatics (2007); University of California, San Diego.  Awards include 2006 Human Proteome Organization (HUPO) Young Investigator Award, 2007 Ph.D. Dissertation Award (CSE/UCSD), 2010 Genome Technology’s Tomorrow’s PI, 2012 Molecular BioSystems’s Emering Investigator and 2013 Sloan Research Fellowship. 

 

Nuno Bandeira, Ph.D. is an Associate Professor of Computer Science and Engineering at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego is also the founding and current Executive Director of the NIH/NIGMS Center for Computational Mass Spectrometry at UCSD. His lab’s research focuses on big data algorithms and systems for worldwide interpretation of proteomics and metabolomics mass spectrometry data, including data from endogenous and digested peptides, discovery and localization of post-translational modifications, protein-protein interactions, sequencing of non-linear peptides with unknown amino acids and characterization of microbial, marine, reptile and plant natural products. As Executive Director of UCSD Center for Computational Mass Spectrometry, his research further extends to distributed algorithms for large scale data analysis (ProteoSAFe), sharing (MassIVE) and crowdsourced, community-wide interpretation (GnPS) of all publicly available mass spectrometry data.

Catherine Brownstein

Catherine Brownstein
Scientific Director, Manton Center for Orphan Disease Research
Boston Children's Hospital
Catherine Brownstein
Scientific Director, Manton Center for Orphan Disease Research
Boston Children's Hospital
 
About Speaker:

Dr. Brownstein is a research associate in Genetics and Genomics, Instructor in Pediatrics, and the manager of the Molecular Genetics Core Facility at Boston Children’s Hospital. Recently named the Scientific Director for the Manton Center for Orphan Disease Research and specializing in gene discovery, Dr. Brownstein has been instrumental in the elucidation of several new disease genes for conditions such as intellectual disability, nemaline myopathy, psychosis, SIDS, and hypophosphatemic rickets. Her current work focuses on advancing the fields of next generation sequencing and analysis, as evidenced in her management of the international CLARITY and CLARITY Undiagnosed competitions.

Melina Cimler

Melina Cimler
Senior Vice President, Quality & Regulatory
Adaptive Biotech
Melina Cimler
Senior Vice President, Quality & Regulatory
Adaptive Biotech
 
About Speaker:

Melina Cimler is Senior Vice President of Regulatory & Quality at Adaptive Biotechnologies. She has over 27 years of experience in the life science and FDA-regulated diagnostic industry leading regulatory, quality systems, clinical affairs, research, and product development organizations.
Prior to joining Adaptive, Dr. Cimler served as Head of Global Quality and Vice President of Quality, Regulatory, Clinical and Government Affairs at Illumina Inc. She defined and executed on the regulatory strategy resulting in the first next generation sequencing platform (Illumina’s MiSeqDx) receiving FDA marketing authorization.
Previously, she held leadership positions in quality, regulatory and government affairs as Senior Vice President at Beckman Coulter Inc. She also served in senior quality, clinical and regulatory roles at Abbott Molecular, Gen-Probe Inc., and C.R. Bard, and as head of Product Development at Epitope, Inc. (now OraSure Technologies). Dr. Cimler holds a Ph.D. in Pharmacology from the University of Washington.

Peter De Hoff

Peter De Hoff
Research Associate, Reproductive Medicine
University of California, San Diego
Peter De Hoff
Research Associate, Reproductive Medicine
University of California, San Diego
 
About Speaker:

Research Associate, Sanford Consortium - Placental Dysfunction Biomarker Discovery Program
Scientist II, Synthetic Genomics Inc. - Tools Development in Algal Biofuels Program
Postdoc, Salk Institute for Biological Studies - Evolution of Mating Systems in Green Algae
PhD, UCLA - Gene Discovery in Legume Rhizobium Symbiosis

Felix W. Frueh

Felix Frueh
Executive Partner
Opus Three
Felix Frueh
Executive Partner
Opus Three
 
About Speaker:

Dr. Felix Frueh is a respected thought leader in personalized medicine with twentyfive years of R&D,
management, and policy experience. He founded Opus Three in 2012 after spending several years at the FDA
and in the payer environment working closely with the pharmaceutical and diagnostic industry.
Dr. Frueh is also Co-Founder and CEO of Intellos Health, a new diagnostic business focused on the development
of affordable tests for the identification of patients requiring confirmatory testing to receive appropriate
therapies.
Prior, he was Chief Scientific Officer at Human Longevity, Inc. and Entrepreneur-in-Residence at Third Rock
Ventures. Dr. Frueh was President of the Medco Research Institute, leading the PBM’s research initiatives in
health economics and outcomes research after having formed Medco’s personalized medicine R&D
organization. Prior to Medco, he was the first Associate Director for Genomics at the FDA, where he oversaw
the development and implementation of policies around biomarker qualification and companion diagnostics.
Dr. Frueh is a Board member at Enterome Biosciences, Ariana Pharmaceuticals, Intellos Health, and
CredibleMeds, and also served on the Board of the Personalized Medicine Coalition. He is a Fellow of the
American College of Clinical Pharmacology and was a faculty member at Georgetown University in
Washington, DC and at the University of North Carolina. Dr. Frueh received his education at Stanford
University and the University of Basel in Switzerland, where he graduated magna cum laude in biochemistry.

Marica Grskovic

Marica Grskovic
Associate Director, R&D
CareDx
Marica Grskovic
Associate Director, R&D
CareDx
 
About Speaker:

Marica Grskovic, Ph.D. is Associate Director, R&D at CareDx, a California based molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for organ transplants. Since joining CareDx in 2012, she has been instrumental in leading the research and development of cell-free DNA, NGS-based diagnostic solutions for rejection surveillance and immunosupressoin monitoring in transplant patients.

Dr. Grskovic received her Ph. D. in Molecular Biology and Biochemistry from the European Molecular Biology Laboratory and University of Heidelberg, Germany.

Gary Gustavsen

Gary Gustavsen
Vice President
Health Advances
Gary Gustavsen
Vice President
Health Advances
 
About Speaker:

Gary Gustavsen joined Health Advances in 2005 and leads its Personalized Medicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, indication prioritization, pricing and reimbursement strategy, system economics, and business development opportunities for both diagnostic and therapeutic clients.
Prior to joining Health Advances, Gary was a researcher at Brookhaven National Lab evaluating a proprietary line of synthetic growth factors. Gary also worked in the Cell & Tissue Technologies group at Becton Dickinson, the Exploratory Cancer Research group at OSI Pharmaceuticals, and most recently the Corporate Strategy group at Millennium Pharmaceuticals. Gary received his Bachelors degree in Biomedical Engineering from Duke University and his Masters degree in Biomedical Engineering from Stony Brook University.

 

 

Zach Hornby

Zach Hornby
Chief Operating Officer
Ignyta
Zach Hornby
Chief Operating Officer
Ignyta
 
About Speaker:

Zachary Hornby brings a dozen years of life sciences business experience to Ignyta. Prior to joining Ignyta, Mr. Hornby was senior director of business development at Fate Therapeutics, where he was responsible for pharmaceutical partnerships and non-dilutive funding. Mr. Hornby has also served in various business and commercial roles at Halozyme Therapeutics (NASDAQ: HALO), Neurocrine Biosciences (NASDAQ: NBIX), and TKT (now Shire Human Genetic Therapies), and he was a life sciences consultant at L.E.K. Consulting. Mr. Hornby is a director of Independa, Inc.

Mr. Hornby holds B.S. and M.S. degrees in biology from Stanford University and an M.B.A. from Harvard Business School.

Bin Li

Bin Li
Director of Computational Biology
Takeda Data Science Institute
Bin Li
Director of Computational Biology
Takeda Data Science Institute
 
About Speaker:

Dr. Bin Li leads a computational biology team at Data Science Institute, Takeda Pharmaceutics. His team provides computational supports on translational medicine research for various Takeda compounds. They also develop methods, build predictive models for biomarker and patient stratification needs, as well as build a cloud-based translational medicine data repository. His team is also responsible on method evaluation and pipeline building for various NGS platforms, including WES, RNA-seq, and targeted NGS panels.

James McNamara

James McNamara
Associate Professor, Department of Internal Medicine
University of Iowa
James McNamara
Associate Professor, Department of Internal Medicine
University of Iowa
 
About Speaker:

Dr. McNamara studied Chemical Engineering at the University of Virginia (B.S., 1992), Neurobiology at Duke University (Ph.D., 2003) and then completed a postdoc at Duke where he developed RNA based therapeutic approaches for cancer. He joined the Department of Internal Medicine at the University of Iowa in 2007. Dr. McNamara’s research is focused on developing rapid clinical diagnostic assays for bacterial infectious diseases based on selective detection of pathogen-derived nuclease activities.

Dobrin Nedelkov

Dobrin Nedelkov
Scientist, Molecular Biomarkers Laboratory
Biodesign Institute, Arizona State University
Dobrin Nedelkov
Scientist, Molecular Biomarkers Laboratory
Biodesign Institute, Arizona State University
 
About Speaker:

Dr. Dobrin Nedelkov is a Scientist and Group Leader of the Molecular Biomarkers Unit in the Biodesign Institute at Arizona State University. He is also a Founding President of the Institute for Population Proteomics.
Dr. Nedelkov received his Ph.D. in Chemistry and Biochemistry from Arizona State University in 1997. After spending a year as a Postdoctoral Associate at Yale University, Dr. Nedelkov joined Intrinsic Bioprobes where over the span of 14 years he progressed through the ranks to ultimately become Scientific Director and CEO of the company, leading the early efforts in technology development for targeted proteomics and protein biomarkers. In 2013 he joined the Biodesign Institute at Arizona State University where he is leading research in proteoform biomarker discovery, validation, and translation.
Dr. Nedelkov has authored over 90 peer reviewed scientific articles, presented at over 60 scientific meetings, has 4 issued patents and several pending patent applications, and has served as a principal investigator on numerous NIH grants.

Alex Parker

Alex Parker
Vice President, Biopharma
Foundation Medicine
Alex Parker
Vice President, Biopharma
Foundation Medicine
 
About Speaker:

Dr. Parker has served as the Vice President of Foundation Medicine’s Business Development team since 2014, where he partners with biopharmaceutical companies to bring transformative cancer care to patients. Alex began his journey at Foundation Medicine in 2010 as the company’s Vice President of Process Technology. Prior to joining Foundation Medicine, Dr. Parker was Principal Scientist at Amgen and held various roles at Millennium Pharmaceuticals. He received his Ph.D in Molecular Genetics from the University of Maine and a bachelor’s in Philosophy and Biology from the University of New Mexico.              

Sandip Patel

Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California, San Diego
Sandip Patel
Assistant Professor, Cancer Immunotherapy Program
University of California, San Diego
 
About Speaker:

Sandip Patel, MD. Assistant Professor, Medical Oncology/Hematology, UC San Diego Moores Cancer Center

Dr. Sandip Patel, MD is a medical oncologist focused on early development of novel immunotherapy, in particular early phase clinical trials of cancer immunotherapy and thoracic oncology immunotherapy trials. His research focus is on predictive biomarkers for immunotherapeutic response and generation of personalized cancer immunotherapy regimens.

He is Assistant Director of the Clinical Trials Office at UCSD Moores Cancer Center and a member of the Cancer Immunotherapy, Experimental Therapeutics (Phase 1), and Thoracic Oncology Programs. Dr. Patel earned his medical degree at Baylor College of Medicine, while performing research at MD Anderson Cancer Center. He completed a residency in Internal Medicine at UCLA Medical Center. He completed a fellowship in Medical Oncology and Hematology at Duke University Medical Center. He is triple board-certified in internal medicine, medical oncology, and hematology.

Lisa Patti-Diaz

Lisa Patti-Diaz
Principal Scientist
Bristol-Myers Squibb
Lisa Patti-Diaz
Principal Scientist
Bristol-Myers Squibb
 
About Speaker:

Lisa Patti-Diaz, MT (ASCP) is a Prinicipal Scientist at Bristol Myers Squib with 17 years experience specializing in developing, validating, and managing flow cytometry assays for biomarker analysis in clinical trials.   Lisa has contributed to biomarker programs in multiple therapuetic areas including immuno-oncology, virology and immunoscience.  Most recently, Lisa has been exploring new technologies that could enable clinical sites to process cells and perform diagnostic flow cytometry-based assays, locally.   Prior to joining BMS, Lisa’s background includes 15 years in clinical laboratory medicine, including oversight of CAP/CLIA certification requirements and educating clinical laboratory scientists.

Melissa Reuter

Melissa Reuter
Associate Director, Business Development, Partnering for Precision Diagnostics
Qiagen
Melissa Reuter
Associate Director, Business Development, Partnering for Precision Diagnostics
Qiagen
 
About Speaker:

Melissa Reuter MS, MBA is Associate Director, Partnering for Precision Diagnostics, Molecular Diagnostics at QIAGEN, where her responsibilities involve establishing and managing partnerships with Pharma clients for the development of Companion Diagnostic assays for approval with their drugs.

Melissa started her career as a Histology Technician at the Johns Hopkins Medical Institution. She then moved into the Life Science industry in 1999 where she worked her way through roles of increasing responsibility in Sales and Account Management until she was National Account Manager for Government and Public Health at QIAGEN in 2013. At this point, Melissa transitioned into a Business Development role with Thermo Fisher’s OEM and Out-licensing team. During this time, she was a key contributor to the incorporation of tools, technologies, and intellectual property into assays of commercial diagnostic developers. Her last role, before returning to QIAGEN, was at Personal Genome Diagnostics (PGDx), where she was Marketing Director. While at PGDx, she assisted in the development of strategies and implementation of promotional tactics to maximize sales, market share, and profitability for PGDx’s in-house tissue and liquid biopsy services and distributed testing model.

Melissa holds a BSc in Biology from the Pennsylvania State University, a MS in Biotechnology from Johns Hopkins University, and a MBA also from Johns Hopkins University.

Anuraag Shrivastav

Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
Anuraag Shrivastav
Associate Professor, Department of Biology
University of Winnipeg
 
About Speaker:

Dr. Anuraag Shrivastav completed his PhD in 2002 from the Banaras Hindu University, India. He received postdoctoral fellowship from Canadian Institutes of Health Research and obtained postdoctoral training at the department of Pathology and Laboratory Medicine and Saskatchewan Cancer Agency, University of Saskatchewan, Canada. Dr Shrivastav is a faculty member at the University of Winnipeg and adjunct member at the University of Manitoba and CancerCare Manitoba. He has published over 40 peer-reviewed articles in International journals of repute. His laboratory is engaged in studying cellular signaling mechanisms that are intricately linked to homeostasis that control cell proliferation, survival and death in cancer cells. Currently, his research group is actively pursuing scientific research to identify novel markers for CRC screening and early detection. Dr. Shrivastav is also Principal, VastCon Inc – A University of Winnipeg spinoff dedicated to developing novel biomarkers based simple prognostic/diagnostic tests.

Steven Skates

Steven Skates
Associate Professor, Medicine
Harvard Medical School
Steven Skates
Associate Professor, Medicine
Harvard Medical School
 
About Speaker:

Steven Skates received his PhD in statistics from the University of Chicago. He joined the Internal Medicine Unit and Radiation Oncology at Massachusetts General Hospital and reviewed a study on the early detection of ovarian cancer using a CA125 cutoff for referral to ultrasound. Since then he has developed algorithms for the early detection of ovarian cancer leveraging the information in longitudinal CA125 values, implemented them in five early detection trials in the US and UK, and led an NCI Early Detection Research Network Biomarker Developmental Laboratory using genomic, proteomic, and longitudinal approaches for discovery and validation of early detection ovarian cancer markers.

Katherine Tynan

Katherine Tynan
President
Tynan Consulting
Katherine Tynan
President
Tynan Consulting
 
About Speaker:

Dr. Tynan is a seasoned biotechnology entrepreneur with a focus on business development, startup entrepreneurship, fundraising and strategic business planning for clinical diagnostic companies and investors. She has a background in product development, financial analysis, operations, regulatory, evidence development, reimbursement and market access for clinical diagnostics in the US and EU. Currently Katherine works with a number of early stage and established diagnostic companies guiding them through product development choices, market entry strategies, funding across a diversified set of indications and technologies. http://www.tynandx.com/

Szilard Voros

Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
Szilard Voros
Founder & Chief Executive Officer
Global Genomics Group
 
About Speaker:

Dr. Szilard Voros, MD, FACC, FSCCT, FAHA is a cardiologist, geneticist and entrepreneur. He is Founder and CEO of Global Genomics Group (“G3”), a precision-medicine-based biotechnology company, developing and commercializing diagnostic biomarkers and novel drug targets for common diseases. G3’s platform is based on the largest-ever program using DNA and RNA sequencing, proteomics, metabolomics, lipidomics and other platforms. G3 has developed a diagnostic blood test for cardiovascular disease and has identified several novel drug targets. Before G3, Voros was Chief Scientific Officer, Chief of Cardiovascular Prevention and Medical Director of Cardiovascular Imaging at Piedmont Heart Institute. He has published extensively in major scientific journals including Nature Reviews, New England Journal of Medicine, Annals of Internal Medicine, Journal of the American College of Cardiology and Circulation: Cardiovascular Genetics, etc.

Xuemei Zhao

Xuemei Zhao
Senior Principal Scientist
Merck
Xuemei Zhao
Senior Principal Scientist
Merck
 
About Speaker:

Xuemei Zhao obtained her Ph.D. in Chemistry at Columbia University and did her postdoctoral training at Cold Spring Harbor Laboratory.  Afterwards, Xuemei joined the Proteomics Department at Merck Research Laboratories.  Her group was responsible for biochemical sample preparation for LC-MS based proteomics profiling in biomarker discovery and new target identification.  Xuemei then moved on to focus on clinical biomarker development and implementation.  Currently, Xuemei leads the immunoassay group in Translational Molecular Biomarkers to support clinical programs across all disease areas at Merck.

Cardiovascular Biomarkers
DISTINGUISHED SPEAKERS
No Records Found
Inflammatory & Immunological Biomarkers
DISTINGUISHED SPEAKERS
Frédéric Baribaud

Frédéric Baribaud
Associate Scientific Director
Janssen
Frédéric Baribaud
Associate Scientific Director
Janssen
 
About Speaker:

Fred is an Associate Director in the Systems Pharmacology & Biomarkers department at Janssen R&D which he joined in 2006. He has been working in various inflammatory diseases working on patient stratification to enable individualized therapeutic treatments.
Fred holds a BS and a MS in Biochemistry from the University of Geneva, Geneva, Switzerland and a PhD in Biology from the University of Lausanne, Lausanne, Switzerland. Fred is a former UPENN postdoctoral fellow where he worked on HIV entry and a former employee of Incyte Inc, were he worked on target validation and was a discovery compound team co-lead for SMI development.

David Choy

David Choy
Principal Scientific Researcher
Genentech
David Choy
Principal Scientific Researcher
Genentech
 
About Speaker:

David Choy is a principal scientific researcher in the department of Biomarker Discovery OMNI at Genentech where he is responsible for biomarker discovery and research strategy for asthma. With a passion for computational, human genetics, and translational biology approaches, his work has contributed to the discovery of periostin, a biomarker of Type 2 asthma.

Yang D. Dai

Yang Dai
Assistant Professor, Immunology & Microbial Science
The Scripps Research Institute
Yang Dai
Assistant Professor, Immunology & Microbial Science
The Scripps Research Institute
 
About Speaker:

2002, received a Ph.D. degree in Immunology from Memorial University of Newfoundland, St John’s, Canada. 2002-2008, postdoctoral fellow in Dr. Eli Sercarz’s lab in Torrey Pines Institute for Molecular Studies, training in immune regulation and T-cell-mediated autoimmune disease. 2008, started independent research career, and studied secreted microvesicles or exosomes in triggering autoimmune responses and type 1 diabetes in non-obese diabetic mice. His lab found that exosomes are potent immunogen and carry unique autoantigens to stimulate autoreactive B and T cells. The findings have been published in Journal of Immunology, European Journal of Immunology and Diabetes. Recent progress in studying candidate autoantigens expressed in the exosomes demonstrated that endogenous retrovirus antigens are enriched in the exosomes and contribute to the autoimmune responses to pancreatic islets.

Justine Debelius

Justine Debelius
Postdoctoral Scholar
University of California, San Diego
Justine Debelius
Postdoctoral Scholar
University of California, San Diego
 
About Speaker:

Justine Debelius is a postdoctoral researcher in the Knight Lab at the University of California, San Diego. Her work focuses on the role of the gut microbiome in the development and management of chronic diseases, especially autoimmune diseases. Dr Debelius received her PhD in 2015 from the University of Colorado, Boulder, where her dissertation focused on the influence of lifestyle factors on the gut microbiome.

Ulrich Hoffmueller

Ulrich Hoffmueller
Founder & Chief Business Officer
Epiontis GmbH
Ulrich Hoffmueller
Founder & Chief Business Officer
Epiontis GmbH
 
About Speaker:

Since the foundation of Epiontis in 2003, in which Uli participated as a founder, he is Chief Business Officer of the company. Prior to founding Epiontis, he worked at Jerini AG, Berlin, Germany (now part of Shire Pharmaceuticals) from 1999 to 2003 as Director of Business Development. Uli completed business school in Berlin, Germany and Cambridge, UK from 2002 to 2004 in parallel to his positions in the biotech industry. He earned his Ph.D. at the Charité University Clinic, Berlin, Germany, in 1998, and was honored with the Charité Research Award in 1997. Uli received his Diplom (Masters) in Biochemistry in 1995 from Humboldt University, Berlin, Germany.

Yinling Hu

Yinling Hu
Ph.D., Senior Investigator
National Cancer Institute
Yinling Hu
Ph.D., Senior Investigator
National Cancer Institute
 
About Speaker:

Yinling Hu is a senior investigation, head of Inflammation Tumorigenesis section, at the Cancer and Inflammation Program, Center for cancer Research, in the National Cancer Institute, NIH. Currently, Hu’s lab is study the role of IKKalpha in skin, lung and esophageal carcinogenesis. Dr. Hu obtained her Ph.D at the University of Melbourne in Australia. She was trained as a postdoc at Michael Karin’s lab of the UCSD in La Jolla California.

Toshiaki Kawakami

Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
Toshiaki Kawakami
Professor, Division of Cellular Biology
La Jolla Institute for Immunology & Allergy
 
About Speaker:

1978 MD, 1983 PhD from The University of Tokyo
1984-88 Postdoc at the NCI/NIH
1990 Assistant Professor, La Jolla Institute for Allergy and Immunology (LJI)
2000 Professor, LJI

Thomas Kleen

Thomas Kleen
Executive Vice President, Immune Monitoring
Epiontis
Thomas Kleen
Executive Vice President, Immune Monitoring
Epiontis
 
About Speaker:

Dr. Kleen is currently Executive VP Immune Monitoring at Epiontis.  Prior he held the position of Director, Business and Technology Development and the function of Director, Assay Development and R&D at CTL, USA He received his Ph.D. in Biology with specialty in Immunology and Virology from the Bayerische Julius-Maximilians-University Würzburg, Bavaria, Germany.  During his studies at Case Western Reserve University in Cleveland, Ohio, he investigated conditions of the human immune system affected by infectious diseases, and in particular the detailed monitoring of immune cell function in patients with human immune deficiency virus (HIV) infections.  He further conducted research on the facilitation of umbilical cord blood stem cell transplantation for immune reconstitution of adult patients with life-threatening hematologic al disorders and malignancies after treatment with full myelo-ablative regimens (http://www.linkedin.com/in/thomasokleen).

His expertise is in the areas of immunology, vaccine and biologic evaluation, immunogenicity and oncology.  One focus is monitoring of Cell Mediated Immunity (CMI) and Bio-markers during immunotherapy, vaccine development and detection of adverse immune reactions during drug development.  He spends significant time educating pharmaceutical entities and governmental agencies about validated, standardized, GLP compliant technologies, which can be deployed today during pre-clinical and clinical trials, for sample logistics and immune monitoring.
Since 2009 Dr. Kleen is member of the SITC-FDA Task Force on Immunotherapy Biomarkers, which focuses on the unique issues related to immunologic monitoring assays as well as novel methodologies for assessing the immune landscape in cancer.

Pierluigi Mauri

Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
Pierluigi Mauri
Chief of Proteomics & Metabolomics
Proteomics and Metabolomics Laboratory - CNR, Institute for Biomedical Tecnologies (ITB-CNR)
 
About Speaker:

Pierluigi Mauri is chief of Proteomics and Metabolomics Labat ITB-CNR. He has a notable experience in the development and application of several technologies (HPLC, capillary electrophoresis, mass spectrometry) for the identification and quantification of several biomolecules in complex matrices. He has been involved in the study of the bioavailabily of several drugs in humans and animals.
He has set-up a proteomics laboratory based on the MudPIT (Multidimensional Protein Identification Technology), a gel-free approch (using two dimensional chromatography coupled to tandem mass spectrometry, 2DC-MS/MS) and a parallel computing system for proteomics. This instrumentation allows for the proteomic profiling of biological samples, without limitations, according to to protein molecular weight, pI or hydrophobicity and guarantees high productivity. Using this methodology, secreted proteins from tumor (FASEB 2005) and immune system cells (JEM, 2011, Immunity, 2016) have been characterized.
Furthermore, direct analysis of biological samples (JMS 2007), enzymatic complexes (Biochimie 2006), development of novel methodological approaches for studying switchredox proteins (JBC 2005 and 2006, JMB 2006), degenerative diseases (Blood, 2012) and structural and functional characterization of proteins (Biol. Chem. 2004, FEBS 2006) have been performed. His main investigations concern molecular profiles obtained by MS-based methodologies and focused on clinical applications (J Proteome Research,
2014; JACC 2013; Nature Commun, 2014; Cardiovasc Res. 2011; Biol Reprod. 2013), including computational methods (J Clin Bioinforma. 2013; Methods Enzymology, 2008) He is co-author of more than 150 scientific publications, he has participated in numerous international congresses and has taught in several metabolomics and proteomics courses.

Stephen Pennington

Stephen Pennington
Professor of Proteomics
University College Dublin
Stephen Pennington
Professor of Proteomics
University College Dublin
 
About Speaker:

Steve graduated from Imperial College of Science and Technology, University of London with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge. During his PhD he was awarded an Elmore Medical Research Fellowship and it was during this fellowship that his interests in the regulation of the mammalian cell cycle began. He was Wellcome Lecturer in the University of Liverpool before moving to Dublin where he is currently Professor of Proteomics in UCD. His research team use a range of proteomics platforms to explore disesase mechanisms and identify biomarkers in oncology and inflammatory disease. Stephen has been awarded a Beit Memorial Fellowship and received a Sir Henry Wellcome Commemorative Award for Innovative Research. He serves on the editorial boards of several journals, and is currenty vice-president of the British Society for Proteome Research, a general council member of the European Proteomics Association and lead organizer of the forthcoming annual congress of the Human Proteome Organisation - HUPO2017 (www.hupo2017.ie).

Geert W. Schmid-Schonbein

Geert Schmid-Schonbein
Distinguished Professor and Chairman, Department of Bioengineering
University of California, San Diego
Geert Schmid-Schonbein
Distinguished Professor and Chairman, Department of Bioengineering
University of California, San Diego
 
About Speaker:

Geert W. Schmid-Schönbein is Distinguished Professor and Chairman of the Department of Bioengineering at the University of California San Diego.  He teaches bioengineering of living tissues and cell and molecular mechanics in heath and disease. His research interest is in molecular/cell mechanics and bioengineering analysis of the microcirculation in disease. His group discovered a fundamental mechanism for cell dysfunctions and inflammation due to “Auto-digestion”.

He is Founding Member of AIMBE, former President of the Biomedical Engineering Society, the Microcirculatory Society and the North American Society of Biorheology, Fellow of the American Heart Association, the Biomedical Engineering Society, the Physiological Society, and the International Federation for Medical and Biological Engineering. He is Past Chair of the World Council for Biomechanics and Member of the US National Academy of Engineering. 

Geert W. Schmid-Schönbein is Distinguished Professor and Chairman of the Department of Bioengineering at the University of California San Diego. He teaches bioengineering of living tissues and cell and molecular mechanics in heath and disease. His research interest is in molecular/cell mechanics and bioengineering analysis of the microcirculation in disease. His group discovered a fundamental mechanism for cell dysfunctions and inflammation due to “Auto-digestion”. He is Founding Member of AIMBE, former President of the Biomedical Engineering Society, the Microcirculatory Society and the North American Society of Biorheology, Fellow of the American Heart Association, the Biomedical Engineering Society, the Physiological Society, and the International Federation for Medical and Biological Engineering. He is Past Chair of the World Council for Biomechanics and Member of the US National Academy of Engineering.

 

 

 

Martin Schwickart

Martin Schwickart
Scientist II
MedImmune
Martin Schwickart
Scientist II
MedImmune
 
About Speaker:

Martin Schwickart, Ph.D. is currently Scientist II in the Department of Clinical Immunology and Bioanalysis at Medimmune in Mountain View, California. Martin leads assay development and data analysis of cellular and soluble biomarkers. He also develops bioanalytical plans including PK, ADA and Nab support. Martin performed his post-doctoral studies at Genentech and his doctoral studies at the Max-Planck Institute of Molecular Cell Biology and Genetics.

Tracy Staton

Tracy Staton
Scientist, OMNI Biomarker Development
Genentech
Tracy Staton
Scientist, OMNI Biomarker Development
Genentech
 
About Speaker:

Tracy completed her graduate studies in the Immunology Program at Stanford University School of Medicine, where she worked in the laboratory of Dr. Eugene Butcher to characterize molecular mechanisms of lymphocyte homing. She then did her postdoctoral training at Harvard University School of Public Health in the laboratory of Dr. Laurie Glimcher. During that time, she studied immune cell development and the importance of effector lymphocyte populations in preclinical models of disease. Tracy came to Genentech in 2011 and holds the position of Scientist in the Biomarker Development group. Her interests are in understanding the mechanisms of action of novel therapeutics in human diseases, and using translational pharmacology to improve the effectiveness of clinical development. At Genentech, she has been involved in developing diagnostic and pharmacodynamic biomarker strategies and assays for programs in asthma.

Neurological Biomarkers
DISTINGUISHED SPEAKERS
Lucie Bruijn

Lucie Bruijn
Chief Scientist
The ALS Association
Lucie Bruijn
Chief Scientist
The ALS Association
 
About Speaker:

Lucie Bruijn, Ph.D. joined The ALS Association in January 2001 as Science Director and Vice President and is currently Chief Scientist for the organization. Prior to that Dr. Bruijn led a team of researchers in drug discovery programs for Parkinson’s and Alzheimer’s disease at Bristol Myers Squibb.

 

Dr. Bruijn received her Bachelor’s degree in Pharmacy at Rhodes University, South Africa.  She received a Master’s degree in Neuroscience and a Ph.D. in Biochemistry, specializing in disease mechanisms of Alzheimer’s disease, at the University of London, United Kingdom. She received her MBA at Imperial College, London, UK. She joined Dr. Don Cleveland’s laboratory at Johns Hopkins University, USA in 1994 where she developed and characterized a mouse model of ALS (mice expressing the familial-linked SOD1 mutation). Using this model her studies focused on disease mechanisms. In addition, in collaboration with Dr. Robert Brown she looked for neurofilament mutations in familial and sporadic ALS patients.

 

At The ALS Association, Dr. Bruijn leads a global research effort.  She has expanded on the existing TREAT ALS™ portfolio to include large international collaborative initiatives in drug development and precision medicine. She has built extensive collaborations internationally and works closely with other ALS funding organizations as well as National Institute of Health. These collaborations ensure that increased dollars are spent on ALS research. She is involved in project development, encouraging partnerships with academia and biotech, and has played a key role in forging collaborations amongst investigators. TREAT ALS has facilitated drug discovery in ALS through its academic and biotech partners and has lead to two recent clinical trials: stem cell therapy for ALS and an antisense approach to reduce the production of mutant SOD1 protein linked to 2 % of ALS. This technology is now being applied to a more recent mutation, C9orf72, identified and linked to 10-12% of all ALS cases and also linked to frontotemporal dementia

 

The Association’s research portfolio also emphasizes the importance of supporting young clinical and scientific investigators and with the funding support through the Safenowitz family and The Greater New York Chapter established the post-doctoral fellowship program at The ALS Association.

 

Dr. Bruijn represents The ALS Association on several scientific and research committees world-wide and acts as advisor to scientists, government officials and industry leaders seeking council in the field of ALS research. She has served as a member of the National Institute of Neurological Disorders and Stroke (NINDS) advisory council. She is the former chair and current member of the integration panel of the Department of Defense (DOD) for the ALS Research Program supporting translational research for ALS and has served on the Data Safety and Monitoring Board for the Neuralstem trial, the first US stem cell trial for ALS. Dr. Bruijn continues to publish in peer-reviewed journals and attends scientific meetings throughout the year to ensure that the research portfolio maximizes opportunities in the field. In her role on the Scientific Advisory Board of Prize4Life Dr. Bruijn has been engaged in developing one of the first Prize concepts for ALS bringing new players into the field. Most recently she has developed an Assistive Technology Prize for communications and a PET Tracer Challenge for TDP43, an abnormally accumulated protein present in ALS and other neurological disorders. These incentives have spurred significant interest from diverse expertise including imaging, biotechnology and bioengineering.

Daniel Chelsky

Daniel Chelsky
Chief Scientific Officer
Caprion Biosciences
Daniel Chelsky
Chief Scientific Officer
Caprion Biosciences
 
About Speaker:

Dr. Chelsky is the CSO at Caprion Biosciences, a company using mass spectrometry to identify and quantify proteins of interest for biomarker discovery and validation, as well as microbiome and host cell protein analysis. Previously he served as President of BioSignal, a subsidiary of PerkinElmer focused on GPCR-related research and reagents. He has also held positions as Sr. Director of Biology at Pharmacopeia, a combinatorial chemistry company, Director of Drug Discovery at Onyx Pharmaceuticals, and Principal Investigator at DuPont Merck Pharmaceuticals. He received his Ph.D. at the University of Oregon and was an American Cancer Society fellow at UC Berkeley.

Clark Chen

Clark Chen
Co-Director of Neurosurgical Oncology
University of California, San Diego
Clark Chen
Co-Director of Neurosurgical Oncology
University of California, San Diego
 
About Speaker:

Dr. Chen is a neurosurgeon with dedicated interest in oncology with focused interest in the study of DNA repair and biomarker development. He received his B.S. in biology from Stanford University, his M.S. in epidemiology from Columbia University, and his M.D., Ph.D. from Harvard Medical School. He subsequently completed his neurosurgery training at the Massachusetts General Hospital, including a clinical fellowship in radiosurgery and a second fellowship on stereotactic neurosurgery. In his thesis work, Dr. Chen studied under Dr. Richard Kolodner to understand how cells maintain chromosomal stability. He then carried out his post-doctoral work with Dr. Alan D’Andrea at the Dana Farber Cancer Institute to understand the pertinence of chromosomal stability in glioblastoma. During this time, he collaborated with Xandra Breakfield to study Extracellular Vesicles (EVs) as a biomarker platform. He currently serves as the chief of stereotactic and radiosurgery and the Vice-Chairman of Neurosurgery at the University of California, San Diego. Dr. Chen is an NIH funded investigator and the recipient of several highly competitive research awards including: the Damon Runyon Fellowship Award, the Burroughs Wellcome Foundation Career Award in Medical Sciences, the Sontag Foundation Distinguished Scientist Award, the Doris Duke Foundation Clinical Scientist Award, and the Forbeck Scholar award. His current work focuses on the mechanisms of governing glioblastoma tumorigenicity, glioblastoma resistance to DNA damaging agents, and the development of predictive and prognostic glioblastoma biomarkers.

Mark Frasier

Mark Frasier
Vice President, Research Programs
Michael J. Fox Foundation
Mark Frasier
Vice President, Research Programs
Michael J. Fox Foundation
 
About Speaker:

Mark Frasier joined the Foundation in 2006. As Vice President, Research Programs, Mark co-manages a team of research professionals who stay closely linked to the Parkinson's research community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson's disease. He also supports the Foundation's priority interest in developing biomarkers for Parkinson's disease that will accelerate clinical trials of new drugs.

Dr. Frasier earned an undergraduate degree in Biochemistry from the University of Dayton and a PhD in Pharmacology from Loyola University Chicago. Prior to joining MJFF, he worked at Eli Lilly, Inc, doing drug discovery within the Neuroscience Discovery Research Group .

Andreas Jeromin

Andreas Jeromin
Chief Medical Officer (consulting)
Quanterix
Andreas Jeromin
Chief Medical Officer (consulting)
Quanterix
 
About Speaker:

Andreas Jeromin, PhD, has more than 25 years of experience in CNS clinical diagnostics and companion diagnostics and co-authors more than 150 publications. He is the founder of Atlantic Biomarkers, Inc., and currently the consulting Chief Medical Officer to Quanterix Corp.

Danni Li

Danni Li
Assistant Professor, Department of Laboratory Medicine and Pathology
University of Minnesota
Danni Li
Assistant Professor, Department of Laboratory Medicine and Pathology
University of Minnesota
 
About Speaker:

Danni Li, PhD, DABCC, is the Director of Clinical Chemistry at the University of Minnesota Medical Center, Fairview and an Assistant Professor of Laboratory Medicine and Pathology at the University of Minnesota, Twin Cities. Dr. Li earned a BS in Chemistry from Zhejiang University in Hangzhou, China in 2002 and a PhD in Analytical Chemistry at the University of Minnesota in 2007. She completed the Clinical Chemistry Fellowship training at the Johns Hopkins University in 2009 and joined the faculty at the Johns Hopkins University in 2010. From January 2010 to August 2012, she was the Director of General Chemistry Laboratories at the Johns Hopkins Hospital and Assistant Professor of Pathology at the Johns Hopkins University. She is a member of American Association for Clinical Chemistry (AACC), and a Diplomat of American Board of Clinical Chemistry (DABCC). She is also a member of American Society of Mass Spectrometry (ASMS). Dr. Li has authored over 20 peer-reviewed research articles, peer-reviewed review articles, editorial, case reports, and book chapters. In last 4 years at the University of Minnesota (2012-2014), Dr. Li has developed her independent research program in applying proteomics and lipidomics to discover plasma biomarkers in Alzheimer’s disease. Recently, she received the 2015 All Investigator Research Grant from the Alzheimer’s Association International Research Grant Program to support her research in plasma biomarkers for Alzheimer’s disease.

Andrew Penn

Andrew Penn
Medical Lead, Stroke Programs, Island Health, Stroke Rapid Assessment Unit
Victoria General Hospital
Andrew Penn
Medical Lead, Stroke Programs, Island Health, Stroke Rapid Assessment Unit
Victoria General Hospital
 
About Speaker:

Dr. Andrew Penn studied neurophysiology and medicine at Cambridge University with post-graduate training in Neurology at UBC. After an MRC fellowship in MR Spectroscopy he spent 8 years on faculty at the University of Alberta in Neurology and Public Health Sciences before returning to Vancouver Island. Here he has worked to establish new systems for region-wide management of acute cerebrovascular syndromes. Funding from the Heart and Stroke Foundation, CIHR and the Canadian Stroke Network has assisted this work. Presently he leads a $10 million project with Genome Canada / Genome BC to develop a tool for distinguishing ACVS from mimic based on clinical and proteomic signatures using mass spectrometry.

Bill Potter

Bill Potter
Senior Advisor
National Institute of Mental Health, NIH
Bill Potter
Senior Advisor
National Institute of Mental Health, NIH
 
About Speaker:
Kira Sheinerman

Kira Sheinerman
Chief Executive Officer
DiamiR Biosciences
Kira Sheinerman
Chief Executive Officer
DiamiR Biosciences
 
About Speaker:

Kira Sheinerman, PhD, is DiamiR’s Co-Founder and CEO. Dr. Sheinerman has worked as a life sciences investment banker for growth biotech companies at H.C. Wainwright, Burrill Securities and Rodman & Renshaw. She is a board member of Boyce Thompson Institute, an affiliate of Cornell University, and co-chair of the Alzheimer’s Association Business Consortium. Dr. Sheinerman received a Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine in New York for her work on molecular mechanisms of Alzheimer's disease.

Gallen Triana-Baltzer

Gallen Triana-Baltzer
Senior Scientist, Neuroscience Biomarkers
Janssen R&D
Gallen Triana-Baltzer
Senior Scientist, Neuroscience Biomarkers
Janssen R&D
 
About Speaker:

Gallen Triana-Baltzer received his doctorate training in Neurobiology at UCSD under the mentorship of Professor Darwin Berg, with a thesis in mechanisms of cholinergic synaptogenesis between neurons. Over the past 10 years he has worked at several biotech/pharma, first as pharmacologist in infectious disease at NexBio, later as translational biologist and project leader in oncology at Covx/Pfizer, and finally as principal scientist in oncology at Phusis. Gallen is currently a Senior Scientist in the Neuroscience Biomarkers group at Janssen R&D, helping to shape and ensure success in biomarker plans for AD and Mood trials.

Yong Zhou

Yong Zhou
Research Scientist
Institute for Systems Biology
Yong Zhou
Research Scientist
Institute for Systems Biology
 
About Speaker:

Dr. Yong Zhou, a Research Scientist at the Institute for Systems Biology (Seattle), has a broad background in mass spectrometry-based proteomics and biomarker discovery in body fluids like blood, urine, CSF and saliva. He has been working on measures of disease-induced changes in whole proteome and post-translational modification sub-proteomes (e.g. glycoproteome and phosphoproteome) using global and targeted mass spectrometry. He has developed effective and highly reproducible blood sample preparation procedures for large-scale biomarker discovery in body fluids. This target proteomics (SRM)-based approach has been applied in multiple projects involving several brain disorders, e.g. PD, AD, TBI and PTSD, and other types of diseases like preterm birth, drug-induced liver toxicity and steatosis, toxoplasmosis and Lyme.

Oncology Biomarkers
DISTINGUISHED SPEAKERS
Jon Armstrong

Jon Armstrong
Chief Scientific Officer
Cofactor Genomics
Jon Armstrong
Chief Scientific Officer
Cofactor Genomics
 
About Speaker:

Jon Armstrong joined Cofactor Genomics in 2009 following 8 years in the TechDev Group at Washington University's Genome Institute. In his current role as CSO, Jon leads Cofactor’s commercialization efforts; directing strategy for new RNA applications and molecular biology products.

Carlos Chan

Carlos Chan
Assistant Professor of Surgery
University of Iowa
Carlos Chan
Assistant Professor of Surgery
University of Iowa
 
About Speaker:

Dr. Carlos Chan is a board-certified surgical oncologist and assistant professor of surgery at the University of Iowa. He obtained his MD and PhD in biochemistry from McGill University in Canada. He subsequently completed his surgical training and post-doctoral research fellowships at McGill University and Harvard Medical School. He has been working on different cancer biomarkers including the carcinoembryonic antigen-related cell adhesion molecules (CEACAM), cathepsin proteases and most recently nucleases.

Darren Davis

Darren Davis
President & Chief Executive Officer
ApoCell
Darren Davis
President & Chief Executive Officer
ApoCell
 
About Speaker:

Dr. Darren Davis received a dual Ph.D. in Cancer Biology and Toxicology at The University of Texas MD Anderson Cancer Center where his worked focused on developing assays to measure the pharmacodynamics effects of investigational targeted therapies. During that time Dr. Davis was the recipient of several institutional and industry awards. Dr. Davis founded ApoCell in 2005 to commercialize innovative "liquid biopsy" solutions that help accelerate the biopharma decision making process for efficient and economical advancement of drug candidates to the regulated clinical market. The company pioneered using rare circulating cells to monitor the effects of drugs in development and later developed a proprietary medical device, ApoStream, that was co-developed/co-funded with the National Cancer Institute. Dr. Davis is the author and co-author of over 100 peer-reviewed publications. Business interviews can be found in Nature Biotechnology, Dow Jones Venture Wire, American Laboratory, The Gray Sheet, Xconomy and The New York Times.

Mark Duncan

Mark Duncan
Professor of Medicine, Senior Director, Proteomic Technology Development
University of Colorado Denver, Biodesix Inc
Mark Duncan
Professor of Medicine, Senior Director, Proteomic Technology Development
University of Colorado Denver, Biodesix Inc
 
About Speaker:

Mark W. Duncan, Ph.D. Senior Director, Proteomic Technology Development, Biodesix Inc.

Mark Duncan received his Ph.D. in chemistry and the neurosciences from the Garvan Institute of Medical Research and the University of New South Wales, Sydney, Australia. His research concentrated on the application of mass spectrometry to the quantification of neurotransmitters, both in human disease and animal models of addiction. Thereafter, he completed a Fogerty postdoctoral fellowship at the NIH, Bethesda, MD, where he explored the role of environmental toxins in neurodegenerative disorders. Mark has held academic appointments (medicine) in Australia, the USA and Saudi Arabia. Although he retains visiting professorships at several institutions, he now works with Biodesix Inc where his attention is focused on the development and delivery of superior diagnostic based on MALDI ToF mass spectrometry.

David Fabrizio

David Fabrizio
Leader Immunotherapy
Foundation Medicine
David Fabrizio
Leader Immunotherapy
Foundation Medicine
 
About Speaker:

David Fabrizio has over 12 years of experience in the drug and biomarker discovery industry, and most recently in the application of next generation sequencing technologies to discover methods for cancer immunotherapy response. David's career began at Adnexus Therapeutics in 2004, where he co-lead the PD1/PDL1 pre-clinical drug discovery program, leading to an acquisition by Bristol Myers Squibb in 2007. While there, his work was awarded several issued patents, including for those describing novel PD-L1, EGFR and IGFR targeting therapeutics, as well as a method for improved drug pharmacokinetics. Additionally, David also invented a novel drug selection technology, ASCENT, to rapidly identify protein based therapeutic binders using a reconstituted mRNA/protein fusion system. In 2013, David joined the startup, AbVitro, and focused on developing an immune cell next-generation sequencing/antigen target identification platform, which was subsequently acquired by Juno Therapeutics. David joined Foundation medicine in 2015, and currently leads the Cancer Immunotherapy group, which is focused on utilizing next-generation sequencing to build methods to identify responders to cancer immunotherapies.

Michael Heller

Michael Heller
Professor
University of California, San Diego
Michael Heller
Professor
University of California, San Diego
 
About Speaker:

Michael J. Heller received his Ph.D. in Biochemistry from Colorado State University in 1973. He was an NIH Postdoctoral Fellow at Northwestern University from 1973 to 1976. Dr. Heller was supervisor of the DNA Technology Group at Amoco Corporation (Standard Oil Indiana) from 1976 to 1984. During that time, he carried out very early bioengineering and recombinant DNA work on plants, algae and photosynthetic bacteria for energy and chemical production. He also development the first fluorescent resonant energy transfer (FRET) and chemiluminescent DNA oligonucleotide probes. Additionally, he oversaw the company sponsored research work at Cetus Corporation on their related recombinant DNA efforts for energy and chemical production, which included the cloning of thermophilic enzymes. Dr. Heller was the Director of Molecular Biology at Molecular Biosystems, Inc., from 1984 to 1987.  He was a co-founder of Integrated DNA Technologies, and served as President and Chief Operating Officer from 1987 to 1989.  He was a co-found of Nanotronics and Nanogen, and served as the Chief Technical Officer from 1993 to 2001. Nanogen carried out the successful development and commercialization of electronic DNA microarray technology for molecular diagnostic genotyping applications. Dr. Heller is now a Professor in the Departments of Nanoengineering and Bioengineering at the University California San Diego. He has also recently co-founded a new company called Biological Dynamics which will be developing new sample to answer cancer diagnostic technology, which is based on novel dielectrophoretic (DEP) microarray technology developed in his lab. Dr. Heller has extensive industrial experience in biotechnology, biomedical and molecular diagnostic devices and nanotechnology; with particular expertise in the areas of DNA probe diagnostics, DC electrophoretic and AC dielectrophoretic devices, DNA synthesis, FRET/fluorescent-based detection technologies and electric field assisted self-assembly of DNA nanocomponents. Dr. Heller has a respectable publication record, and has been an invited speaker to many scientific conferences and meetings related clinical/molecular diagnostics, DNA microarrays, biosensors, lab-on-a-chip devices, bio-MEMS and nanotechnology. He has over 50 issued US patents related to microelectronic chips, microarrays and integrated devices for DNA hybridization, miniaturized sample to answer diagnostic devices, biosensors, genomics, proteomics, nanotechnology and nanofabrication, nano-based DNA optical storage and for fluorescent energy transfer in DNA nanostructures. Dr. Heller has been a panel member for the White House (OSTP) National Nanotechnology Initiative 1999/2000; the NAS (NAE) Review of National Nanotechnology Initiative 2001-2002; the NAS(NAE) – Engineer for the 2020 - 2001/2002; and has also been involved in a number of NSF Nanotechnology Workshops.

Jennifer Jones

Jennifer Jones
Staff Clinician, Center for Cancer Research
NIH, NCI/CCR
Jennifer Jones
Staff Clinician, Center for Cancer Research
NIH, NCI/CCR
 
About Speaker:

Dr. Jones (McIntire) positionally cloned the TIM gene family and demonstrated the genetic association between TIMs and immune response profiles (McIntire et al., Nature Immunology 2001, and Nature 2003). As a radiation oncologist, her current research is focused on developing immune-based therapies that synergize with radiation to produce optimal anti-tumor immune responses.

Tumor cells, immune cells, and irradiated tissues release large quantities of biologically active (and distinct) nanoscale extracellular vesicles (e.g., exosomes and microparticles). Dr. Jones is developing improved methods to characterize, sort, and perform functional studies of nanoparticles, with a dedicated focus on the preparation, analysis, counting, and cytometric study of extracellular vesicles in the setting of cancers and immune responses.

Noah Malmstadt

Noah Malmstadt
Associate Professor of Chemical Engineering & Materials Science & Biomedical Engineering
University of Southern California
Noah Malmstadt
Associate Professor of Chemical Engineering & Materials Science & Biomedical Engineering
University of Southern California
 
About Speaker:

Noah Malmstadt received his bachelor’s degree in Chemical Engineering at Caltech in 1997 and received his PhD in Bioengineering from the University of Washington in 2003, working under the supervision of Profs. Patrick Stayton and Allan Hoffmann. Following postdoctoral work with Prof. Jacob Schmidt at the University of California at Los Angeles, in 2007 he joined the faculty of the University of Southern California, where he is now an Associate Professor of Chemical Engineering & Materials Science, Biomedical Engineering, and Chemistry. He has pioneered the adaption of ionic liquid-based nanoparticle synthesis chemistry to flow reactors and the development of modular 3D microreactors for bioanalytics.

Mark Matijevic

Mark Matijevic
Associate Director, Translational Biomedicine, Eisai AiM Institute
Eisai
Mark Matijevic
Associate Director, Translational Biomedicine, Eisai AiM Institute
Eisai
 
About Speaker:
Shivani Sharma

Shivani Sharma
Associate Director, Nano and Pico Characterization Lab
California Nanosystems Institute, University of California, Los Angeles
Shivani Sharma
Associate Director, Nano and Pico Characterization Lab
California Nanosystems Institute, University of California, Los Angeles
 
About Speaker:

Dr. Shivani Sharma holds a PhD in Biomedical Engineering and is Associate Director at the California NanoSystems Institute (CNSI) at University of California-Los Angeles, California, USA. Her expertise includes developing novel cell and tissue mechanics based biomarkers for cancer detection and chemosensitivity assays; high-resolution structural and mechanical mapping of exosomes, bio-molecules; and single molecule force spectroscopy for diagnostic and drug delivery applications. She leads the nanobiology R&D applications at the Nano & Pico Characterization Lab at CNSI.

She is a founding member of the International Society for Extracellular vesicles (ISEV), has chaired sessions as well as delivered invited talks at several International/National conferences related to exosomes and cancer diagnostics. She currently serves on the Editorial boards for Journal of Extracellular Vesicles and Journal of Circulating Biomarkers. Dr Sharma's work has featured in Chemical & Engineering News, Global Medical Discovery.com, Asia Research News and won the Physical Sciences Entrepreneurship and Innovation Award.

Laszlo Takacs

Laszlo Takacs
Chief Executive Officer & Chief Scientific Officer, R&D
Biosystems International Kft. Hungary
Laszlo Takacs
Chief Executive Officer & Chief Scientific Officer, R&D
Biosystems International Kft. Hungary
 
About Speaker:

Laszlo Takacs, is Professor of Human Genetics at the University of Debrecen, Hungary, he is also the CEO / CSO for Biosystems International. Dr. Takacs worked at Pfizer and Amgen in various management roles in biotech and drug R&D and translational medicine area. Dr. Takacs was the head of the Special Unit of NIAAA, National Institute of Health.

 

Amy Wehn

Amy Wehn
Senior Manager, Immuno-oncology Biomarker Development Programs
HTG Molecular Diagnostics
Amy Wehn
Senior Manager, Immuno-oncology Biomarker Development Programs
HTG Molecular Diagnostics
 
About Speaker:

Amy Wehn received her Ph.D. from the University of Pittsburgh in Molecular Biology. She then completed a post-doctoral fellowship at the University of North Carolina Lineberger Comprehensive Cancer Center, utilizing genome-wide screening to uncover biomarkers and drug targets for rational combinatorial chemotherapeutic design. Amy then moved into industry where she has held various client-facing, consultative positions in the immuno-oncology field. In her current position at HTG Molecular, Amy works directly with biopharma clients to develop strategies for deployment of HTG's low-input, extraction-free targeted RNA sequencing technology in clinical trials and companion diagnostic programs.

Chan Whiting

Chan Whiting
Associate Director
Aduro Biotech
Chan Whiting
Associate Director
Aduro Biotech
 
About Speaker:

Dr. Chan Whiting is currently the Director of Immune Monitoring and Biomarker Development at Aduro Biotech. She received her Ph.D. at UCLA in the Department of Microbiology and Immunology where her thesis focused on identifying and characterizing novel signal transducers involved in cytokine and T cell receptor (TCR) signaling pathways. She did post-doctoral training in chemokine biology at Amgen followed by research into E3 ligases in the development of autoimmune diseases at Stanford University. Prior to joining Aduro Biotech, Dr. Whiting has worked for systems biology companies including Entelos, Inc. and Ingenuity Systems (currently Qiagen) in developing mathematical mechanistic models and other in silico computational tools for target discovery and validation for autoimmunity, infectious diseases and oncology. She applies systems-based technologies along with traditional immune assays towards biomarker development efforts in immune oncology at Aduro. She is also the project team lead for personalized medicine program at Aduro.